Skip to main content

UNC-CH NORC July 2020 Newsletter

July 6, 2020

UNC-CH NORC July 2020 Newsletter

Categories: Featured News, News, Newsletters Tags: University of North Carolina at Chapel Hill

UNC-CH NORC April 2020 Newsletter

June 15, 2020

UNC-CH NORC April 2020 Newsletter

Categories: Featured News, News, Newsletters, Uncategorized Tags: University of North Carolina at Chapel Hill

UNC-CH NORC January 2020 Newsletter

June 15, 2020

UNC-CH NORC January 2020 Newsletter

Categories: Featured News, News, Newsletters Tags: University of North Carolina at Chapel Hill

NORCH Bulletin May 2020

June 15, 2020

NORCH Newsletter May 2020 (Issue #21)

Categories: Featured News, News, Newsletters, Uncategorized

NORCH Bulletin March 2020

June 15, 2020

NORCH Newsletter March 2020 (Issue #20)

Categories: Featured News, News, Newsletters, Uncategorized

NORCH Bulletin January 2020

January 27, 2020

NORCH Newsletter January 2020 (Issue #19)

Categories: Featured News, News, Newsletters Tags: Harvard Medical School

NORCH Bulletin November 2019

November 21, 2019

NORCH Newsletter November 2019 (Issue #18)

Categories: Featured News, News, Newsletters Tags: Harvard Medical School

NORCH Bulletin September 2019

October 18, 2019

NORCH Bulletin September 2019 (Issue #17)

Categories: Featured News, News, Newsletters Tags: Harvard Medical School

NORCH Bulletin June 2019

September 6, 2019

NORCH Bulletin June 2019 (Issue #16)

Categories: Featured News, News, Newsletters Tags: Harvard Medical School

NORCH Bulletin April 2019

April 5, 2019

NORCH Bulletin April 2019 Research Spotlight: SGLT2 Inhibition Reprograms Systemic Metabolism via FGF21-Dependent and – Independent Mechanisms  Sodium/glucose cotransporter-2 (SGLT2) inhibitors are a relatively new class of antidiabetic medications that inhibit renal glucose reabsorption, increasing glucosuria and lowering serum glucose. More recently, SGLT2 inhibitors have been shown to cause modest weight loss, improve cardiovascular risk, and reduce mortality – effects that are not adequately explained by increased glucosuria. Drs. Patti, Gerszten, and colleagues used an integrated transcriptomic-metabolomics approach to identify molecular mediators of the SGLT2 inhibitor canagliflozin in obese, non-diabetic mice. Results demonstrate that SGLT2 inhibitors modulate key nutrient-sensing pathways, activating 5’ AMP-activated protein kinase (AMPK), inhibiting mechanistic target of rapamycin (mTOR), … Read More »

Categories: Featured News, News, Newsletters Tags: Harvard Medical School